LMNL - Liminal Biosciences closes divestiture of plasma collection centers

Liminal BioSciences (LMNL) announces that it has closed the previously announced divestment of its 2 plasma collection centers, Prometic Plasma Resources and Prometic Plasma Resources ((USA)) to Kedrion S.p.A.Have also entered into an option agreement granting Kedrion the right to acquire the remainder of the company's plasma-derived therapeutics business by June 15, 2021, including the Ryplazim business.The total consideration for the 2 plasma collection centers and the option, was $17M, which Liminal received upon closing.Shares down marginally during after-market trading.

For further details see:

Liminal Biosciences closes divestiture of plasma collection centers